Literature DB >> 12543746

Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation.

J A Montero1, J M Ruiz-Moreno.   

Abstract

AIMS: To analyse the visual and angiographic results of photodynamic therapy (PDT) with verteporfin in highly myopic patients with subfoveal choroidal neovascularisation (CNV).
METHODS: PDT was performed on highly myopic patients with subfoveal CNV. The patient population was divided into two groups according to age at onset of CNV (group 1 aged < or = 55 and group 2 aged >55 years old). Best corrected visual acuity (BCVA) and angiographic findings were considered.
RESULTS: At the end of follow up group 2 had worse BCVA than group 1. 76% of patients in both groups showed a complete closure of CNV at the end of follow up.
CONCLUSION: Visual prognosis of myopic CNV treated by PDT is influenced by age at onset.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12543746      PMCID: PMC1771483          DOI: 10.1136/bjo.87.2.173

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  17 in total

1.  Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients.

Authors:  J M Ruiz-Moreno; C de la Vega
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

2.  Visual function after foveal translocation with 360-degree retinotomy and simultaneous torsional muscle surgery in patients with myopic neovascular maculopathy.

Authors:  T Fujikado; M Ohji; S Kusaka; A Hayashi; M Kamei; A A Okada; K Oda; Y Tano
Journal:  Am J Ophthalmol       Date:  2001-01       Impact factor: 5.258

3.  Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.

Authors: 
Journal:  Ophthalmology       Date:  2001-05       Impact factor: 12.079

4.  Pathologic myopia and choroidal neovascularization.

Authors:  M L Hotchkiss; S L Fine
Journal:  Am J Ophthalmol       Date:  1981-02       Impact factor: 5.258

5.  Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization.

Authors:  H Tabandeh; H W Flynn; I U Scott; M L Lewis; P J Rosenfeld; F Rodriguez; A Rodriguez; L J Singerman; J Schiffman
Journal:  Ophthalmology       Date:  1999-11       Impact factor: 12.079

6.  Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups.

Authors:  Takeshi Yoshida; Kyoko Ohno-Matsui; Yoshiteru Ohtake; Takayuki Takashima; Soh Futagami; Takayuki Baba; Kenjiro Yasuzumi; Takashi Tokoro; Manabu Mochizuki
Journal:  Ophthalmology       Date:  2002-04       Impact factor: 12.079

7.  Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes.

Authors:  J M Ruiz-Moreno; J A Montero
Journal:  Eur J Ophthalmol       Date:  2002 Mar-Apr       Impact factor: 2.597

8.  Natural history of choroidal neovascularization in degenerative myopia.

Authors:  M P Avila; J J Weiter; A E Jalkh; C L Trempe; R C Pruett; C L Schepens
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

9.  Macular translocation for surgical management of subfoveal choroidal neovascularizations in patients with AMD: first results.

Authors:  S Wolf; A Lappas; A W Weinberger; B Kirchhof
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1999-01       Impact factor: 3.117

10.  The burden of genetically determined eye disease.

Authors:  J S Green; J C Bear; G J Johnson
Journal:  Br J Ophthalmol       Date:  1986-09       Impact factor: 4.638

View more
  20 in total

Review 1.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

2.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Javier A Montero; Jose M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

3.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Amy L Wong; David T L Liu; Dennis S C Lam
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

4.  Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia.

Authors:  Ariko Kojima; Kyoko Ohno-Matsui; Satoshi Teramukai; Yoko Ishihara; Noriaki Shimada; Takeshi Yoshida; Yoshiharu Sugamoto; Takashi Tokoro; Manabu Mochizuki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-04-21       Impact factor: 3.117

5.  Intravitreal bevacizumab versus photodynamic therapy for myopic choroidal neovascularization in a North-African population.

Authors:  Leila El Matri; Fedra Kort; Ahmed Chebil; Rim Bouraoui; Ahlem Merdassi; Mejda Bouladi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-12       Impact factor: 3.117

6.  Reply to: Effect of axial length on myopic choroidal neovascularization.

Authors:  Jiang-Hui Wang; Wei Jiang; Ze-Feng Kang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-01-05       Impact factor: 3.117

7.  Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.

Authors:  Jose M Ruiz-Moreno; Javier A Montero; Pedro Amat-Peral
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-01-14       Impact factor: 3.117

8.  Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia.

Authors:  Ute E K Schnurrbusch; Claudia Jochmann; Peter Wiedemann; Sebastian Wolf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-15       Impact factor: 3.117

9.  Photodynamic therapy for inflammatory choroidal neovascularisation unresponsive to immunosuppression.

Authors:  T Leslie; N Lois; D Christopoulou; J A Olson; J V Forrester
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

10.  Indocyanine green angiographic features of myopic subfoveal choroidal neovascularization as a prognostic factor after photodynamic therapy.

Authors:  Suk Ho Byeon; Oh Woong Kwon; Sung Chul Lee; Sung Soo Kim; Hyoung Jun Koh
Journal:  Korean J Ophthalmol       Date:  2006-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.